2,121
Views
1
CrossRef citations to date
0
Altmetric
Pain Management

Changes in prescription pain medication and intra-articular corticosteroid utilization after intra-articular bio-fermentation derived hyaluronic acid use in patients undergoing multimodal pain management

, , ORCID Icon, , &
Pages 7-13 | Received 03 Aug 2021, Accepted 19 Nov 2021, Published online: 06 Dec 2021

References

  • American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee: evidence-based guideline. 2nd edition. [Published 2013; cited 2018 March 15]. Available from: https://www.aaos.org/research/guidelines/TreatmentofOsteoarthritisoftheKneeGuideline.pdf
  • Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589.
  • Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45(4 Suppl):S3–S11.
  • Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American college of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220–233.
  • Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44(3):253–263.
  • Kijowski R. Risks and benefits of intra-articular corticosteroid injection for treatment of osteoarthritis: what radiologists and patients need to know. Radiology. 2019;293(3):664–665.
  • Wernecke C, Braun HJ, Dragoo JL. The effect of intra-articular corticosteroids on articular cartilage: a systematic review. Orthop J Sports Med. 2015;3(5):232596711558116.
  • American Academy of Orthopaedic Surgeons. Management of osteoarthritis of the knee (non-arthroplasty). Evidence-based clinical practice guideline. 3rd Edition. [Published 2021; cited 2021 Oct 8]. Available from: https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-the-knee/oak3cpg.pdf
  • Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015;16:321.
  • Altman RD, Rosen JE, Bloch DA, et al. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Semin Arthritis Rheum. 2009;39(1):1–9.
  • Waddell DD, Bricker DC. Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg. 2010;19(01):19–27.
  • Altman RD, Rosen JE, Bloch DA, et al. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label extension study of the FLEXX trial. Osteoarthritis Cartilage. 2011;19(10):1169–1175.
  • Chitnis AS, Etter K, Holy CE, et al. Real world impact of the high concentration non-avian high molecular weight hyaluronan on pain medication use among osteoarthritis patients. Curr Med Res Opin. 2019;35(9):1523–1527.
  • McIntyre LF, Beach W, Bhattacharyya S, et al. Impact of hyaluronic acid injections on utilization of pain management medications. Am J Pharma Benefits. 2017;9(6):195–199.
  • Niazi F, Ong KL, Kidd VD, et al. Decrease in opioid and intra-articular corticosteroid burden after intra-articular hyaluronic acid for knee osteoarthritis treatment. Pain Manag. 2020;10(6):387–397.
  • Ong KL, Stoner KE, Yun BM, et al. Baseline and postfusion opioid burden for patients with low back pain. Am J Manag Care. 2018;24(8):e234–e240.
  • Ferring Pharmaceuticals Inc. Product information. Euflexxa (1% sodium hyaluronate). [Published 2016; Cited 2020 Nov 3]. Available from: http://www.euflexxa.com/wp-content/uploads/2019/09/Patient-Information.pdf
  • Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician. 2014;17(2):E119–128.
  • Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain. 2008;24(6):469–478.
  • Herzig SJ, Rothberg MB, Cheung M, et al. Opioid utilization and opioid-related adverse events in nonsurgical patients in US hospitals. J Hosp Med. 2014;9(2):73–81.
  • Kessler ER, Shah M, Gruschkus SK, et al. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33(4):383–391.
  • Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part I–evidence assessment. Pain Physician. 2012;15(3 Suppl):S1–S65.
  • Altman R, Fredericson M, Bhattacharyya SK, et al. Association between hyaluronic acid injections and time-to-Total knee replacement surgery. J Knee Surg. 2016;29(7):564–570.
  • Altman R, Lim S, Steen RG, et al. Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large U.S. Health claims database. PLOS One. 2015;10(12):e0145776.
  • Dasa V, Lim S, Heeckt P. Real-World evidence for safety and effectiveness of repeated courses of hyaluronic acid injections on the time to knee replacement surgery. Am J Orthop. 2018;47(7). DOI:10.12788/ajo.2018.0058
  • Etter K, Chitnis AS, Holy CE, et al. High-concentration nonavian high-molecular weight hyaluronan injections and time-to-total knee replacement surgery. J Comp Eff Res. 2020;9(11):795–805.
  • Ong KL, Anderson AF, Niazi F, et al. Hyaluronic acid injections in medicare knee osteoarthritis patients are associated with longer time to knee arthroplasty. J Arthroplasty. 2016;31(8):1667–1673.
  • Ong KL, Runa M, Lau E, et al. Is Intra-Articular injection of synvisc associated with a delay to knee arthroplasty in patients with knee osteoarthritis? Cartilage. 2019;10(4):423–431.
  • Phillips M, Bhandari M, Grant J, et al. A systematic review of current clinical practice guidelines on intra-articular hyaluronic acid, corticosteroid, and platelet-rich plasma injection for knee osteoarthritis: an international perspective. Orthop J Sports Med. 2021;9(8):23259671211030272.
  • Altman RD, Bedi A, Karlsson J, et al. Product differences in intra-articular hyaluronic acids for osteoarthritis of the knee. Am J Sports Med. 2016;44(8):2158–2165.
  • Phillips M, Vannabouathong C, Devji T, et al. Differentiating factors of intra-articular injectables have a meaningful impact on knee osteoarthritis outcomes: a network meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2020;28(9):3031–3039.
  • Hummer CD, Angst F, Ngai W, et al. High molecular weight intraarticular hyaluronic acid for the treatment of knee osteoarthritis: a network meta-analysis. BMC Musculoskelet Disord. 2020;21(1):702.
  • Shewale AR, Barnes CL, Fischbach LA, et al. Comparative effectiveness of intra-articular hyaluronic acid and corticosteroid injections on the time to surgical knee procedures. J Arthroplasty. 2017;32(12):3591–3597 e3524.
  • Nicholls M, Manjoo A, Shaw P, et al. Rheological properties of commercially available hyaluronic acid products in the United States for the treatment of osteoarthritis knee pain. Clin Med Insights Arthritis Musculoskelet Disord. 2018;11:1179544117751622.